A promising new treatment for the aggressive cancer mesothelioma has passed an important step of its development, as the Australian biotechnology firm AdAlta announced that its experimental CAR T-cell therapy EW-001 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA).
The move comes just three months after AdAlta reported clinical data that showed that a patient with advanced mesothelioma had complete tumor response and no cancer recurrence for two years after receiving a single dose of the therapy.
AdAlta is currently in preparation for a Phase 1 clinical study of the treatment, and EW-001 receiving Orphan Drug designation should help expedite the treatment’s review and availability should it become ready for market.
What Is EW-001 for Mesothelioma?
EW-001 is a class of cancer treatment called a chimeric antigen receptor (CAR) T-cell therapy, a form of immunotherapy that focuses on engineering and boosting the body’s immune cells to help it fight cancer.
In CAR T-cell therapy, providers collect T-cells from the patient’s bloodstream, then genetically modify and multiply them in a laboratory setting in order to boost their effectiveness against cancer. Then, they re-infuse them into the patient’s bloodstream, setting them off to attack cancer cells.
CAR T-cell therapy has historically proven quite effective against blood cancers such as leukemia and lymphoma. Although solid tumor cancers such as mesothelioma have been a tougher nut to crack, a number of recent studies have shown that significant progress is being made.
AdAlta’s previous clinical results indicate EW-001’s effectiveness against mesothelioma. Not only did they report complete response – meaning all detectable signs of cancer in the body have disappeared after treatment – in two of the 10 patients in the study treated at higher doses, but all five remaining on study in March were still alive and in follow-up by August.
Although a 20% complete response rate may seem modest, it would represent a significant improvement on most other advanced mesothelioma treatments, which generally report complete response rates at or near zero.
If these results are sustained through a coming Phase 1 study, they could provide a major affirmation for CAR-T’s utility in treating mesothelioma.
What Does Orphan Drug Designation Mean for EW-001?
Orphan Drug status is a designation created by the FDA for treatments targeting rare diseases such as mesothelioma, in order to incentivize manufacturers to create drugs for conditions that may not be as profitable to combat.
The Orphan Drug designation, while not a guarantee of future FDA approval, carries with it incentives such as tax breaks for clinical testing, waivers for marketing applications, and a potential seven years of market exclusivity after approval.
AdAlta is now proceeding apace with preparations for its Phase 1 clinical trial and its first Australian manufacturing runs, following a meeting with the FDA that it said raised “no issues” with its manufacturing, testing, and Phase 1 design.
Sources & Author
- AdAlta receives U.S. orphan-drug designation for EW-001. TipRanks. Retrieved from https://www.tipranks.com/news/company-announcements/adalta-receives-u-s-orphan-drug-designation-for-ew-001. Accessed 11/17/2026.
- EW-001 IIT study overall survival update. Listcorp. Retrieved from: https://www.listcorp.com/asx/1ad/adalta-limited/news/ew-001-iit-study-overall-survival-update-3387319.html. Accessed on 11/17/2026.